| 1 |
NCT02522650 |
Recruiting |
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria |
|
- Drug: Amiloride
- Drug: Triamterene
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 24 hr urine protein excretion
- urine plasmin activity
- urine plasminogen activity
- (and 2 more...)
|
30 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02522650 |
2013-0496 |
|
July 2013 |
October 2019 |
October 2019 |
August 13, 2015 |
October 13, 2017 |
|
- Georgetown University
Washington, D.C., District of Columbia, United States
|
|
| 2 |
NCT01094327 |
Recruiting |
Proteinuria in Pre and Post Transplant |
|
|
Observational
|
|
|
Other |
- Observational Model: Other
- Time Perspective: Retrospective
|
|
100 |
All |
up to 25 Years (Child, Adult) |
NCT01094327 |
20070206 |
|
February 2008 |
December 2018 |
December 2018 |
March 26, 2010 |
February 8, 2018 |
|
- University of Miami Miller School of Medicine Transplant Clinic
Miami, Florida, United States
|
|
| 3 |
NCT03550859 |
Not yet recruiting
New |
HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria |
- Chronic Kidney Disease
- Proteinuria
|
- Drug: Telmisartan/Rosuvastatin 40/10mg
- Drug: Telmisartan 40mg
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of change from baseline to week 48 in Urine Protein to Creatinine Ratio (UPCR)
- Change from baseline to week 24 in UPCR
- Change from baseline to week 24 and week 48 in Urine Albumin-to-Creatinine Ratio (UACR)
- (and 11 more...)
|
374 |
All |
19 Years and older (Adult, Older Adult) |
NCT03550859 |
YMC030 |
|
June 2018 |
June 2019 |
June 2019 |
June 8, 2018 |
June 8, 2018 |
|
- Korea University Ansan Hospital
Ansan, Korea, Republic of
|
|
| 4 |
NCT03190694 |
Recruiting |
Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria |
- Chronic Kidney Diseases
- Proteinuria
|
|
Interventional
|
Phase 2 |
- Hiddo Lambers Heerspink
- AstraZeneca
- University Medical Center Groningen
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change in 24-hr proteinuria with dapagliflozin for six weeks relative to placebo in patients with non-diabetic kidney disease and proteinuria 500 mg/day on stable angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment.
- Effect of dapagliflozin 10 mg/d compared to placebo on Glomerular Filtration Rate (GFR) using iohexol clearance
- Effect of dapagliflozin 10 mg/d compared to placebo on systolic/diastolic blood pressure
- (and 3 more...)
|
50 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03190694 |
2017003001
2017-001090-16 |
DIAMOND |
November 12, 2017 |
July 16, 2019 |
December 1, 2019 |
June 19, 2017 |
May 4, 2018 |
|
- Nephrology Dept., Vancouver Coastal Health Research Institute
Vancouver, British Columbia, Canada - Division of Nephrology University Health Network, University of Toronto
Toronto, Ontario, Canada - Nephrology Unit, University Kebangsaan Malaysia
Kuala Lumpur, Malaysia - (and 4 more...)
|
|
| 5 |
NCT02798042 |
Recruiting |
Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery? |
- Acute Kidney Injury
- Obesity
- Proteinuria
|
|
Observational
|
|
- New York University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
1800 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02798042 |
16-00775 |
|
June 2016 |
September 2018 |
June 2019 |
June 14, 2016 |
November 22, 2017 |
|
- NYU Langone Medical Center
New York, New York, United States
|
|
| 6 |
NCT03510286 |
Not yet recruiting |
Validation of a PrCr Dipstick Diagnostic Test in Ghana |
|
- Diagnostic Test: Test-it™ PrCr Urinalysis Strips
|
Observational
|
|
- PATH
- Kintampo Health Research Centre, Ghana
- United States Agency for International Development (USAID)
|
Other / U.S. Fed |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Accuracy of the PrCr dipstick test compared to a laboratory reference assay (chemistry analyzer measurement of protein and creatinine)
- Accuracy of the PrCr dipstick test compared to a protein only dipstick.
|
3000 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03510286 |
1133673-2 |
|
May 2018 |
September 2018 |
September 2018 |
April 27, 2018 |
April 30, 2018 |
|
|
|
| 7 |
NCT03019848 |
Recruiting |
Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney Disease |
|
- Dietary Supplement: Curcumin
- Other: Placebo
|
Interventional
|
Phase 2 |
- Instituto Nacional de Cardiologia Ignacio Chavez
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Urine protein excretion
- Free radical scavenging activity
- Malondialdehyde (MDA)
- Proinflammatory status
|
100 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03019848 |
INC.12-793 |
|
May 2016 |
May 2017 |
May 2017 |
January 13, 2017 |
January 13, 2017 |
|
- Instituto Nacional de Cardiologia Ignacio Chávez
Mexico City, Mexico
|
|
| 8 |
NCT02972346 |
Recruiting |
Availability Study of ACTH to Treat Children SRNS/SDNS |
|
|
Interventional
|
Not Applicable |
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- 24-hour proteinuria excretion
- times of relapse
|
42 |
All |
3 Years to 12 Years (Child) |
NCT02972346 |
XH-16-044 |
|
November 2016 |
December 2018 |
June 2019 |
November 23, 2016 |
November 23, 2016 |
|
- Xinhua Hospital
Shanghai, Shanghai, China
|
|
| 9 |
NCT02532790 |
Recruiting |
The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children |
- Henoch-Schoenlein Purpura Nephritis
|
- Drug: Prednisone
- Drug: ACEI
|
Interventional
|
Phase 2 |
- Nanjing Children's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Disappearance of proteinuria
- Disappearance of hematuria
- Renal function
|
100 |
All |
2 Years to 16 Years (Child) |
NCT02532790 |
AiZhang |
|
August 2015 |
July 2018 |
July 2018 |
August 26, 2015 |
April 3, 2018 |
|
- Nanjing Children's Hospital
Nanjing, Jiangsu, China
|
|
| 10 |
NCT02633046 |
Recruiting |
Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS |
- Idiopathic Focal Segmental Glomerulosclerosis
|
- Drug: Acthar 80 U 2x/week
- Other: Placebo 80 U 2x/week
- Drug: Acthar 80 U 3x/week
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Complete and partial remission of proteinuria at Week 24.
|
236 |
All |
18 Years and older (Adult, Older Adult) |
NCT02633046 |
MNK14224049 |
PODOCYTE |
May 16, 2016 |
June 2021 |
June 2021 |
December 17, 2015 |
February 28, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - AKDHC Medical Research Services, LLC
Glendale, Arizona, United States - Mallinckrodt Investigational Site
Tempe, Arizona, United States - (and 79 more...)
|
|
| 11 |
NCT02765594 |
Recruiting |
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy |
|
- Drug: Hydroxychloroquine Sulfate
- Drug: Valsartan
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Remission (Complete [CR] or Partial [PR]) at Week 24
- Change from Baseline in Proteinuria Levels at the Indicated Time Points
- Change from Baseline in Serum Creatinine Levels at the Indicated Time Points
- (and 6 more...)
|
98 |
All |
18 Years to 60 Years (Adult) |
NCT02765594 |
PUMCHHCQIgAN01 |
HCQIgAN |
June 2016 |
May 2019 |
June 2019 |
May 6, 2016 |
September 20, 2017 |
|
- Peing Union Medical College Hospital
Beijing, China
|
|
| 12 |
NCT03341949 |
Recruiting |
Soluble CD146 and Proteinuria in Chronic Renal Disease |
|
- Biological: Recurring blood sample
|
Interventional
|
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Serum CD146s assay
- The dosage of proteinuria
|
205 |
All |
18 Years and older (Adult, Older Adult) |
NCT03341949 |
2017-12
ID RCB |
CPinMRC |
December 1, 2017 |
December 1, 2019 |
December 1, 2019 |
November 14, 2017 |
November 14, 2017 |
|
- Assistance Publique Hôpitaux de Marseille
Marseille, France
|
|
| 13 |
NCT03149068 |
Not yet recruiting |
Studying the Relationship Between Mean Platelet Volume and Neutrophil/ Lymphocyte Ratio With Inflammation and Proteinuria in Chronic Kidney Disease |
- Evaluation of Early Inflammatory Process in CKD
|
|
Observational
|
|
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Studying the Relationship Between Mean Platelet Volume and Neutrophil/ Lymphocyte Ratio With Inflammation and Proteinuria in Chronic Kidney Disease
|
100 |
All |
19 Years to 65 Years (Adult, Older Adult) |
NCT03149068 |
Assuit University 96 |
|
July 1, 2017 |
May 1, 2018 |
May 1, 2018 |
May 11, 2017 |
May 16, 2017 |
|
|
|
| 14 |
NCT03502031 |
Recruiting |
Spironolactone & RAAS: Effect on Urinary Proteinuria & Mean Epidermal Growth Factor Receptor |
- Renal Insufficiency, Chronic
- Diabetic Nephropathy Type 2
|
- Drug: ACE inhibitor
- Drug: ARB
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Long term change in eGFR with combination treatment with ACE/ARB and Spironolactone
- Will combination therapy with RAAS blockers and Spironolactone be superior to RAAS inhibitor alone to lower UP/Cr ratio
- Will combination therapy with RAAS blockers and Spironolactone have same protein lower effect in both African Americans versus Caucasians?
- (and 2 more...)
|
164 |
All |
18 Years and older (Adult, Older Adult) |
NCT03502031 |
NN-01 |
|
March 1, 2018 |
December 2020 |
December 2020 |
April 18, 2018 |
April 18, 2018 |
|
- NephroNet
Buford, Georgia, United States
|
|
| 15 |
NCT02599532 |
Recruiting |
Pharmacokinetics of Apixaban in Nephrotic Syndrome |
- Nephrotic Syndrome
- Proteinuria
|
|
Interventional
|
Phase 1 |
- University of North Carolina, Chapel Hill
- North Carolina Translational and Clinical Sciences Institute
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Area under the concentration versus time curve after single dose (AUC) of apixaban
- Mean terminal phase plasma half-life (t½)
- Apparent oral clearance (CL/F)
- (and 3 more...)
|
30 |
All |
18 Years to 79 Years (Adult, Older Adult) |
NCT02599532 |
14-1455
550KR161709 |
|
April 30, 2017 |
April 2019 |
April 2019 |
November 6, 2015 |
May 11, 2018 |
|
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
|
|
| 16 |
NCT03195023 |
Recruiting |
Effect of RAS Blockers on Chronic Kidney Disease Progression in Elderly Patients With Non Proteinuric Nephropathies |
- Renal Insufficiency, Chronic
- Proteinuria
|
- Drug: Lisinopril
- Drug: Amlodipine
|
Interventional
|
Phase 4 |
- Hospital General Universitario Gregorio Marañon
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Chronic kidney disease progression
- Security of RAS blockers in elderly patients
- Effect of RAS blockers on mortality in elderly patients
- Effects of RAS blockers on cardiovascular risk in elderly patients
|
106 |
All |
65 Years and older (Older Adult) |
NCT03195023 |
PROERCAN01 |
PROERCAN01 |
June 2015 |
June 2018 |
June 2021 |
June 22, 2017 |
June 22, 2017 |
|
- Gregorio Maranon Hospital
Madrid, Spain
|
|
| 17 |
NCT00001978 |
Recruiting |
Determination of Kidney Function |
- Kidney Disease
- Proteinuria
- Autoimmune / Connective Tissue Diseases
|
|
Observational
|
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
9999999 |
All |
7 Years and older (Child, Adult, Older Adult) |
NCT00001978 |
890152
89-DK-0152 |
|
August 24, 1989 |
|
|
January 21, 2000 |
May 17, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 18 |
NCT03015974 |
Recruiting |
Registry of IgA Nephropathy in Chinese Children |
- IgA Nephropathy
- Proteinuria in Nephrotic Range
- Immunosuppressive Treatment
|
- Drug: Corticosteroid
- Drug: Cyclophosphamide
- Drug: Mycophenolate mofetil
- (and 2 more...)
|
Observational
|
|
- Peking University First Hospital
- Nanjing PLA General Hospital
- Beijing Children's Hospital
- (and 22 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Improvement of proteinuria
- Renal dysfunction
- Hypertension
- (and 2 more...)
|
1200 |
All |
1 Month to 18 Years (Child, Adult) |
NCT03015974 |
2015[992] |
RACC |
January 2016 |
January 2018 |
January 2019 |
January 10, 2017 |
January 11, 2017 |
|
- Peking University First Hospital
Beijing, China
|
|
| 19 |
NCT02818192 |
Recruiting |
Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study) |
- Type 2 Diabetes
- Proteinuria
- Stress
- Nephropathy
|
|
Observational
|
|
- University of Manitoba
- Canadian Institutes of Health Research (CIHR)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Persistent Albuminuria
- Change in albumin excretion over time.
- Change in estimated glomerular filtration rate (eGFR) over time.
|
400 |
All |
10 Years to 18 Years (Child, Adult) |
NCT02818192 |
B2011:024 |
iCARE |
January 2017 |
March 2020 |
August 2020 |
June 29, 2016 |
April 4, 2017 |
|
- Children's Hospital Research Institute of Manitoba/University of Manitoba
Winnipeg, Manitoba, Canada
|
|
| 20 |
NCT02373241 |
Recruiting |
Preventing Sickle Cell Kidney Disease |
- Anemia, Sickle Cell
- Sickle Cell Disease
- Kidney Disease
- (and 2 more...)
|
|
Interventional
|
Phase 2 |
- University of Alabama at Birmingham
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility as measured by the number of patients that accept enrollment, remain adherent to losartan, and remain adherent to study procedures.
- Feasibility as measured by number of patients with adverse events to losartan.
- To prospectively evaluate the incidence of hypertension (clinic and ambulatory) in patients with SCD and number of patients with abnormal blood pressure biomarkers.
- Feasibility as measured by the number of patients with improvement in nocturnal blood pressure while receiving losartan.
|
40 |
All |
5 Years to 25 Years (Child, Adult) |
NCT02373241 |
F141107009
1K23HL127100-01 |
|
April 2015 |
April 2020 |
April 2020 |
February 26, 2015 |
May 1, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States
|
|
| 21 |
NCT02973178 |
Recruiting |
Scanadu Urine Device Validation Study Protocol |
- Urinary Tract Infections
- Proteinuria
- Ketone Urine
- (and 2 more...)
|
- Device: Scanadu Urine Device
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Diagnostic
|
- Usability: % successful scans in three tests conducted by lay users in following the app on the iPhone and obtain user experience on questionnaire
- Method Comparison: Conduct two tests by following iPhone app (self and patient samples), results in concordance with professional testers; achieve accuracy in different concentrations of six urine analytes each using approximately 20 samples per level.
- Reproducibility: Lay user's ability to repeat a urine test nine times by following iPhone app and obtain nine results that are in concordance.
|
300 |
All |
18 Years and older (Adult, Older Adult) |
NCT02973178 |
FO-004 |
|
August 2016 |
December 2016 |
December 2016 |
November 25, 2016 |
November 25, 2016 |
|
- West Coast Research, LLC
Mountain View, California, United States - West Coast Research, LLC
San Leandro, California, United States
|
|
| 22 |
NCT00977977 |
Recruiting |
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy |
- Nephrotic Syndrome
- Proteinuria
- Autoimmune Disease
- (and 2 more...)
|
- Drug: Rituximab Infusion
- Drug: Oral Cyclosporine
|
Interventional
|
Phase 2 |
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of complete and partial remissions; duration of remissions
- Safety; percent reduction in proteinuria
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT00977977 |
090223
09-DK-0223 |
|
September 1, 2009 |
January 1, 2020 |
January 1, 2020 |
September 16, 2009 |
March 29, 2018 |
|
- National Naval Medical Center
Bethesda, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 23 |
NCT01783795 |
Recruiting |
Dent Disease Mutation Genotyping |
|
- Genetic: Genetic Analysis
|
Interventional
|
Not Applicable |
- Mayo Clinic
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Number of subjects with genetic mutations in either the CLCN5 or ORCL1 gene
|
180 |
All |
Child, Adult, Older Adult |
NCT01783795 |
10-006442
U54DK083908 |
|
August 2012 |
June 2018 |
June 2018 |
February 5, 2013 |
June 20, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
|
| 24 |
NCT02442921 |
Recruiting |
Colchicine for Diabetic Nephropathy Trial |
|
- Drug: Colchicine
- Drug: Placebo
|
Interventional
|
Phase 1
Phase 2 |
- Sheba Medical Center
- D-Cure, Israel
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change of urinary protein excretion ( mg/24hrs) from baseline to 18 months.
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT02442921 |
SHEBA-2015-1560-SK-CTIL |
CDNT |
February 22, 2016 |
April 30, 2019 |
April 30, 2019 |
May 13, 2015 |
May 9, 2017 |
|
- Sheba Medical Center
Ramat Gan, Israel
|
|
| 25 |
NCT03415074 |
Not yet recruiting |
Could Ketoanalogue-supplemented Low Protein Diet Defer Dialysis in Advanced Diabetic Kidney Disease? (K-DDD) |
|
- Behavioral: Protein restriction
|
Interventional
|
Not Applicable |
- Anemia Working Group Romania
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- CKD progression
- Need for renal replacement therapy (RRT)
- Patients' Quality of life
- (and 16 more...)
|
120 |
All |
18 Years to 85 Years (Adult, Older Adult) |
NCT03415074 |
AnemiaWGRomania |
K-DDD |
March 1, 2018 |
September 30, 2020 |
March 31, 2021 |
January 30, 2018 |
February 6, 2018 |
|
- "Dr Carol Davila" Teaching Hospital of Nephrology
Bucharest, Romania
|
|
| 26 |
NCT03376282 |
Recruiting |
Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy |
|
- Other: Hyperbaric Oxygen oxygen therapy (HBOT)
|
Interventional
|
Phase 2 |
- Assaf-Harofeh Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- glomerular filtration rate
- proteinuria
- renal blood flow (BOLD)
- fibrosis (DWI MRI)
|
20 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03376282 |
84-15 |
|
January 2016 |
December 2018 |
June 2019 |
December 18, 2017 |
December 18, 2017 |
|
- Dialysis Clinic in Asaf Harofhe Medical Center
Zerifin, Israel
|
|
| 27 |
NCT03170336 |
Recruiting |
A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein |
|
- Drug: Amiloride
- Drug: Hydrochlorothiazide
|
Interventional
|
Phase 4 |
- Guangdong General Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- The remission of proteinuria
- estimated Glomerular Filtration Rate
- creatinine
- hyperkalemia
|
54 |
All |
14 Years and older (Child, Adult, Older Adult) |
NCT03170336 |
GGH2016422H |
ANTI-UPRO |
March 1, 2018 |
June 1, 2019 |
June 1, 2019 |
May 31, 2017 |
March 19, 2018 |
|
- Nephrology Dept,Guangdong General Hospital
Guangzhou, Guangdong, China
|
|
| 28 |
NCT02682407 |
Recruiting |
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 |
|
- Biological: OMS721
- Other: Vehicle (D5W)
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety as assessed by the incidence of adverse events up until the last visit at Week 104.
- Assessment of the safety of OMS721 on laboratory measures.
- Assess the effect of OMS721 on proteinuria.
|
44 |
All |
18 Years and older (Adult, Older Adult) |
NCT02682407 |
OMS721-GNP-001 |
|
February 2016 |
December 2018 |
December 2018 |
February 15, 2016 |
January 16, 2018 |
|
- Omeros Investigational Site
Denver, Colorado, United States - Omeros Investigational Site
Augusta, Georgia, United States - Omeros Investigational Site
Evergreen Park, Illinois, United States - (and 4 more...)
|
|
| 29 |
NCT02721342 |
Recruiting |
Remission Clinic in Proteinuric Chronic Nephropathies |
|
- Drug: Ramipril, Irbesartan and Atorvastin
|
Observational
|
|
- Mario Negri Institute for Pharmacological Research
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Glomerular Filtration Rate (GFR) estimated
- 24 hour proteinuria
- Number of participants with fatal and non-fatal cardiovascular events
|
1500 |
All |
18 Years and older (Adult, Older Adult) |
NCT02721342 |
Remission Clinic |
|
June 2009 |
December 2018 |
March 2019 |
March 29, 2016 |
December 19, 2017 |
|
- Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò
Ranica, Bergamo, Italy - Ospedale Morgagni - Pierantoni - U.O. Nefrologia e Dialisi
Forlì, Forli', Italy - Asl 6 Sanluri-P.O. Nostra Signora di Bonaria - U.O. Nefrologia e Dialisi
San Gavino- Monreale, Medio Campidano - VS, Italy - (and 10 more...)
|
|
| 30 |
NCT02194582 |
Recruiting |
Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure |
- Focal Segmental Glomerulosclerosis
- Nephrotic Syndrome
- End Stage Renal Disease
- (and 2 more...)
|
|
Observational
|
|
- Beth Israel Deaconess Medical Center
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- United States Department of Defense
|
Other / NIH / U.S. Fed |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- To identify the genetic causes of FSGS, NS, and idiopathic proteinuria/ESRD in patients and families
|
2050 |
All |
Child, Adult, Older Adult |
NCT02194582 |
2009P000430
5R01DK054931-18 |
FSGS |
June 1996 |
January 2035 |
January 2035 |
July 18, 2014 |
March 20, 2018 |
|
- BIDMC
Boston, Massachusetts, United States
|
|
| 31 |
NCT03141970 |
Recruiting |
Prednisolone Trial in Children Younger Than 4 Years |
|
|
Interventional
|
Phase 3 |
- All India Institute of Medical Sciences, New Delhi
- NephCure Accelerating Cures Institute
- University of Michigan
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Relapse of nephrotic syndrome during 12 months after randomization
- Number of relapses during 12 months follow up
- Time to first relapse (days)
- (and 5 more...)
|
156 |
All |
1 Year to 4 Years (Child) |
NCT03141970 |
v1.0
CTRI/2015/06/005939 |
|
July 1, 2015 |
March 31, 2020 |
March 31, 2022 |
May 5, 2017 |
May 5, 2017 |
|
- Cedars-Sinai Medical Center, Pediatric IBD & Pediatric Nephrology
Los Angeles, California, United States - Stanford University Medical Center, Department of Pediatrics, Division of Nephrology
Stanford, California, United States - University of Michigan Department of Pedatric Nephrology
Ann Arbor, Michigan, United States - (and 2 more...)
|
|
| 32 |
NCT03004001 |
Recruiting |
Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome |
|
- Drug: Alirocumab
- Drug: Alirocumab placebo
- Drug: Atorvastatin
|
Interventional
|
Not Applicable |
- Gloria Vega
- Regeneron Pharmaceuticals
- Aventis Pharmaceuticals
- Dallas VA Medical Center
|
U.S. Fed / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Levels of plasma lipoproteins
- Levels of PCSK9
- Triglyceride-rich lipoproteins (Remnants)
- Lipidomics
|
20 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03004001 |
VA16-029 |
|
January 2017 |
December 2018 |
December 2018 |
December 28, 2016 |
March 13, 2017 |
|
- DallasVAMC
Dallas, Texas, United States
|
|
| 33 |
NCT03357653 |
Not yet recruiting |
Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1 |
- Glomerulonephritis, Immunoglobulin A (IgA)
|
- Drug: Losartan group
- Drug: Placebo group
|
Interventional
|
Phase 3 |
- Ewha Womans University
- The Catholic University of Korea
- Kyung Hee University Hospital at Gangdong
- (and 15 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Significant proteinuria rate
- Proteinuria remission rate
- Impaired kidney function rate
- Hypertension development rate
|
174 |
All |
19 Years and older (Adult, Older Adult) |
NCT03357653 |
BEST-IGAN-001 |
BEST-IgAN-1 |
January 30, 2018 |
December 31, 2021 |
December 31, 2021 |
November 30, 2017 |
November 30, 2017 |
|
|
|
| 34 |
NCT03445247 |
Recruiting |
Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy |
- Diabetic Nephropathy Type 2
|
- Other: Extracorporeal low-intensity shockwave
|
Interventional
|
Not Applicable |
- Chang Gung Memorial Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- changes of estimated glomerular filtration rate
- changes of proteinuria
- changes of systolic and diastolic blood pressure
|
60 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03445247 |
104-7771A |
|
July 1, 2017 |
June 30, 2019 |
June 30, 2020 |
February 26, 2018 |
February 26, 2018 |
|
- Kaohsiung Chang-Gung Memorial Hospital
Kaohsiung, Please Select, Taiwan
|
|
| 35 |
NCT01881542 |
Recruiting |
Standard 24-hour Urine Protein vs Shorter Period for Diagnosis of Pre-eclampsia |
|
|
Observational
|
|
- HaEmek Medical Center, Israel
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- to validate a shorter urine collection time for assessment of proteinuria
- To examine if a shorter urine collection time for assessment of proteinuria is comparable to the standard 24 hours
|
307 |
Female |
18 Years to 55 Years (Adult) |
NCT01881542 |
0157-12-EMC |
PET and urine |
June 2013 |
October 2018 |
December 2018 |
June 19, 2013 |
March 27, 2018 |
|
- HaEmek Medical Center
Afula, Israel
|
|
| 36 |
NCT03396328 |
Not yet recruiting |
Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria |
|
- Behavioral: conventional low salt education
- Behavioral: Intensive low salt dietary education by smartphone application
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Decrements of 24-hour urine albumin levels
- Decrements of 24-hour urine sodium
- Change of blood pressure with a sphygmomanometer
|
176 |
All |
19 Years to 65 Years (Adult, Older Adult) |
NCT03396328 |
4-2017-0906 |
|
February 2018 |
November 2018 |
November 2019 |
January 10, 2018 |
January 11, 2018 |
|
- Division of Nephrology, Department of Internal Medicine Yonsei University College of Medicine
Seoul, Korea, Republic of
|
|
| 37 |
NCT03470701 |
Not yet recruiting |
Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit |
- Albuminuria
- Chronic Kidney Diseases
- Cardiovascular Diseases
- Hypertension
|
- Other: Mailed Urinalysis Smartphone Kit
|
Interventional
|
Not Applicable |
- Geisinger Clinic
- National Kidney Foundation
- Healthy.io Ltd.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Completion of albuminuria screening
- Total number of detected albuminuria cases
- Achievement of optimal albuminuria treatment
|
1000 |
All |
18 Years and older (Adult, Older Adult) |
NCT03470701 |
2017-0516 |
|
April 2018 |
July 2018 |
December 2018 |
March 20, 2018 |
March 21, 2018 |
|
|
|
| 38 |
NCT02945969 |
Recruiting |
Sodium Lowering and Urinary Protein Reduction Trial |
- Chronic Kidney Disease
- Albuminuria
|
- Behavioral: Low Sodium Diet
|
Interventional
|
Phase 3 |
- Tulane University School of Public Health and Tropical Medicine
- Tulane University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Net Change in Urinary Albumin-to-Creatinine Ratio (ACR)
- Net Change in Urinary Albumin
- Estimated Glomerular Filtration Rate (eGFR)
- (and 2 more...)
|
150 |
All |
21 Years and older (Adult, Older Adult) |
NCT02945969 |
1P20GM109036-P1
1P20GM109036 |
SUPER |
November 2016 |
November 2018 |
November 2018 |
October 26, 2016 |
June 19, 2017 |
|
- Tulane University
New Orleans, Louisiana, United States
|
|
| 39 |
NCT02795676 |
Recruiting |
Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function |
|
- Biological: PRX-102 (pegunigalsidase alfa)
- Biological: agalsidase beta
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- eGFR Slope
- Left Ventricular Mass Index (g/m2) by MRI
- Plasma Lyso-Gb3
- (and 8 more...)
|
78 |
All |
18 Years to 60 Years (Adult) |
NCT02795676 |
PB-102-F20 |
BALANCE |
June 2016 |
March 2019 |
June 2019 |
June 10, 2016 |
January 23, 2018 |
|
- UAB Medicine
Birmingham, Alabama, United States - University of California Los Angeles
Los Angeles, California, United States - University of California Irvine Center
Orange, California, United States - (and 40 more...)
|
|
| 40 |
NCT02497300 |
Recruiting |
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease |
- Chronic Kidney Disease
- Albuminuria
|
- Drug: Spironolactone
- Drug: Amiloride
|
Interventional
|
Phase 2 |
- University of Alabama at Birmingham
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent change in flow-mediated dilation
- Change in oxidative stress as measured by urine levels of F2-isoprostanes
- Change in albuminuria
- (and 2 more...)
|
62 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02497300 |
F140508008 |
VEMAKD |
March 2015 |
July 2019 |
July 2020 |
July 14, 2015 |
August 18, 2017 |
|
- Hypertension Research Clinic at UAB
Birmingham, Alabama, United States
|
|
| 41 |
NCT02231125 |
Recruiting |
Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy |
|
- Drug: Losartan
- Drug: Abelmoschus manihot
|
Interventional
|
Phase 4 |
- Chen Xiangmei
- Jiangsu Suzhong Pharmaceutical Group Co., Ltd.
- Chinese PLA General Hospital
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- Change in 24-h proteinuria from baseline after treatment
- Change in serum creatinine from baseline after treatment
- Change in estimated glomerular filtration rate (eGFR) from baseline after treatment
|
1600 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02231125 |
S2014-039-01 |
|
September 2014 |
July 2016 |
December 2017 |
September 4, 2014 |
July 6, 2016 |
|
- The First Hospital of Anhui Medical University
Hefei, Anhui, China - The Second Hospital of Anhui Medical University
Hefei, Anhui, China - Beijing Chao-yang Hospital
Beijing, Beijing, China - (and 85 more...)
|
|
| 42 |
NCT03025828 |
Recruiting |
Adrenocorticotropic Hormone in Membranous Nephropathy |
|
|
Interventional
|
Phase 4 |
- Icahn School of Medicine at Mount Sinai
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Remission of proteinuria
- 24h Proteinuria
- Estimated Glomerular Filtration Rate (GFR)
- (and 3 more...)
|
25 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03025828 |
GCO 16-2402 |
|
March 19, 2018 |
February 2019 |
February 2019 |
January 20, 2017 |
March 21, 2018 |
|
- Icahn School of Medicine at Mount Sinai
New York, New York, United States
|
|
| 43 |
NCT02734472 |
Recruiting |
Blood Pressure Follow-up Study in Two Chinese Cohorts(C-BPCS) |
|
- Other: Incidence and risk factors of hypertension
|
Observational
|
|
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- blood pressure value(mmHg)
- Left ventricular hypertrophy（g/m^2）
- Increased arterial stiffness（mm/s）
- (and 2 more...)
|
5298 |
All |
6 Years to 60 Years (Child, Adult) |
NCT02734472 |
XJTU1AF-CRF-2015-006 |
C-BPCS |
July 2016 |
December 2017 |
December 2018 |
April 12, 2016 |
October 2, 2017 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 44 |
NCT02712346 |
Recruiting |
The Role of Endothelin-1 in Sickle Cell Disease |
|
- Drug: Ambrisentan
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Augusta University
- Gilead Sciences
- National Heart, Lung, and Blood Institute (NHLBI)
|
Other / Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Safety and Tolerability of ambrisentan in patients with sickle cell disease measured by physical exam, vital signs, blood and urine testing, ECG (specified visits), concomitant medication review, adverse events review
- Efficacy of ambrisentan in improving kidney function in patients with sickle cell disease measured by blood
- Efficacy of ambrisentan in decreasing TRJ velocity
- (and 5 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02712346 |
Endothelin
5U01HL117684 |
|
September 2015 |
May 2018 |
May 2018 |
March 18, 2016 |
June 29, 2017 |
|
- Augusta University
Augusta, Georgia, United States
|
|
| 45 |
NCT02808429 |
Recruiting |
Efficacy and Safety of Atacicept in IgA Nephropathy |
|
- Drug: Atacicept 25 mg
- Drug: Atacicept 75 mg
- Drug: Placebo
- Drug: Atacicept 150 mg
|
Interventional
|
Phase 2 |
- EMD Serono Research & Development Institute, Inc.
- Merck KGaA
- EMD Serono
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Part A: Proportion of subjects with Adverse events (AE), AEs of special interest (AESIs), serious AEs, AEs leading to discontinuation, and AEs leading to death
- Part B: Percent change from baseline in proteinuria at Week 48
- Part A: Serum atacicept concentrations
- (and 18 more...)
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT02808429 |
MS700461-0035
2016-002262-31 |
|
January 31, 2017 |
May 4, 2021 |
August 17, 2022 |
June 21, 2016 |
May 31, 2018 |
|
- Research site
Glendale, Arizona, United States - Research site
California City, California, United States - Research site
Chula Vista, California, United States - (and 16 more...)
|
|
| 46 |
NCT00071526 |
Recruiting |
Urinary Vitamin C Loss in Diabetic Subjects |
- Diabetes Type 1
- Diabetes Type 2
- Healthy Volunteers
|
|
Observational
|
|
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Plasma, neutrophil and RBC Vitamin C concentrates
- Correlate urinary vitamin C excretion with urinary protein loss
- Urinary vitamin C loss in relation to plasma vitamin C concentrations.
- (and 3 more...)
|
99999999 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00071526 |
040021
04-DK-0021 |
|
October 27, 2003 |
|
|
October 28, 2003 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
|
| 47 |
NCT03531255 |
Not yet recruiting
New |
Multi-center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
|
Interventional
|
Phase 3 |
- Apellis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence and severity of hematologic treatment-emergent adverse events
- Mean change from baseline to 48 weeks in hemoglobin levels (g/dL)
|
109 |
All |
18 Years and older (Adult, Older Adult) |
NCT03531255 |
APL2-307 |
|
August 7, 2018 |
December 20, 2020 |
December 20, 2020 |
May 21, 2018 |
May 21, 2018 |
|
|
|
| 48 |
NCT03500549 |
Not yet recruiting |
Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH |
- Paroxysmal Nocturnal Hemoglobinuria
|
|
Interventional
|
Phase 3 |
- Apellis Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
70 |
All |
18 Years and older (Adult, Older Adult) |
NCT03500549 |
APL2-302 |
|
May 2018 |
July 2019 |
December 2019 |
April 17, 2018 |
April 17, 2018 |
|
|
|
| 49 |
NCT03472885 |
Recruiting |
A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab |
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
- Drug: ACH-0144471
- Drug: Eculizumab
|
Interventional
|
Phase 2 |
- Achillion Pharmaceuticals
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Hemoglobin (Hgb) During the 24-Week Treatment Phase Compared to Baseline: Optimal Dose Group
- Median Hemoglobin (Hgb) During the 24-Week Treatment Phase Compared to Baseline: Non-Optimal Dose Groups
- Number of Units of Red Blood Cells (RBCs) Transfused During 24 Weeks of Treatment
- (and 4 more...)
|
12 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03472885 |
ACH471-101
2016-003526-16
U1111-1209-4655 |
PNH |
May 8, 2018 |
June 30, 2019 |
December 31, 2019 |
March 21, 2018 |
May 28, 2018 |
|
- John Hopkins
Baltimore, Maryland, United States - Cleveland Clinic
Cleveland, Ohio, United States
|
|
| 50 |
NCT03439839 |
Recruiting |
Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) |
- Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
|
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Reduction of chronic hemolysis
- C3 deposition
- Profile of Pharmacokinetics: Maximum plasma concentration (Cmax)
- (and 4 more...)
|
10 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03439839 |
CLNP023X2201
2017-000888-33 |
|
April 9, 2018 |
December 17, 2018 |
December 17, 2018 |
February 20, 2018 |
April 24, 2018 |
|
- Novartis Investigative Site
Essen, Germany - Novartis Investigative Site
Napoli, Italy
|
|
Create an RSS feed from your search for:
Download the search results for: